Paras Healthcare IPO asks 171 times first full-year profit for a leveraged regional hospital chain

1. IPO Overview

Paras Healthcare is raising about Rs 1,450 cr at Rs 660 to Rs 693 a share, through Rs 500 cr of new shares and Rs 950 cr of shares sold by existing owners, which means most of the money does not stay with the company. At the top of the band, Rs 693 a share, the company is valued at Rs 7,498.34 cr on a post-issue basis.

Two things stand out about this deal. The sale by existing owners is almost twice the fresh raise, so this is largely an exit rather than a growth raise. And the pricing comes after a return to annual profit in FY26 following losses in FY24 and FY25, with pre-IPO borrowings still far larger than equity. The fresh issue earmarks Rs 375 cr for debt repayment, so historical leverage must be read alongside that planned reduction (RHP p.130).

2. What the company does

Runs eight hospitals across the north and east

Paras Healthcare runs a network of eight hospitals across North India, Bihar and Jharkhand. It is a clinical, specialty-led hospital platform, which in plain words means doctors organised around specialties such as cardiac sciences, orthopaedics, neurosciences, oncology and mother-and-child care run the medical work, rather than a collection of general clinics.

For a retail reader, it helps to picture what that means on the ground. Each hospital has beds, operation theatres, intensive care units, emergency rooms, imaging such as MRI and CT, laboratories and pharmacies. Patients come for consultations, get admitted for surgery or medical treatment, and the hospital bills for room stay, doctor fees, procedures, drugs and tests.

Tertiary care means advanced treatment that a small nursing home cannot do, such as joint replacement, bypass surgery or cancer surgery. Quaternary care is a step beyond that, very complex work such as organ transplants or advanced neurosurgery. These treatments need costly equipment, trained teams and intensive care backup, so they earn higher revenue per patient but also need heavy fixed investment.

Earns money per bed, per procedure and per visit

Hospitals like these earn in three broad ways. Inpatient care, where a patient is admitted for a few days, brings the largest bills because it bundles room rent, surgery, implants, drugs and intensive care. Outpatient visits bring smaller but frequent fees for consultations, scans and follow-ups. Health checks, diagnostics and pharmacy sales add steady volumes around those two.

Growth for such a chain usually comes from filling more beds, treating more complex cases that pay more per bed, adding new beds or hospitals, and getting patients to return for follow-up care. Costs are largely fixed in the short run, since doctors, nurses, rent and equipment must be paid whether a bed is full or empty. That is why occupancy, which is the share of beds filled on an average day, and average revenue per occupied bed decide whether a hospital makes money.

At June 30, 2026, Paras had 2,211 beds, of which 1,502 were operational, and occupancy of 69.72%. FY26 occupancy was 61.75%, up from 50.78% in FY25, while average revenue per occupied bed per day was Rs 47,397.82 against Rs 48,088.57. These disclosures show stronger utilisation alongside a small decline in average daily revenue per occupied bed; they do not support an explanation based solely on higher prices. The RHP also discloses specialty mix: oncology contributed 21.63% and cardiac sciences 12.78% of FY26 revenue (RHP pp.155–156).

Serves patients in its catchment, paid by families and insurers

The customers are patients and their families living within driving distance of each hospital, plus patients referred from smaller towns for advanced surgery. In North India, Bihar and Jharkhand, many patients pay from savings or borrowings, while a growing share is paid by private health insurance, employer cover and government schemes.

Who pays matters because it decides how fast the hospital gets cash. Cash patients pay at discharge. Insured patients and government schemes pay after claims are checked, which can take weeks or months. Hospitals with more insured and scheme patients often show higher receivables, which is money billed but not yet collected.

FY26 revenue mix was 33.88% self-pay, 24.84% insurance/TPA and 41.28% government schemes and PSUs. The last category rose from 30.91% in FY25, making reimbursement terms and collection discipline material to the business. Inpatient revenue was Rs 1,256.753 cr and outpatient revenue Rs 285.917 cr in FY26; the filing therefore allows readers to examine both the payor and treatment-channel mix (RHP pp.156, 469).

Competes as a regional chain against pan-India leaders

Paras Healthcare is positioned as a multi-location operator, which means it runs several hospitals under one brand and shared systems for doctors, purchase, quality and finance. Its listed comparisons are large pan-India names such as Apollo Hospitals, Fortis Healthcare, Global Health, Aster DM Quality Care and others, which run far larger networks and earn revenue across many states.

Scale helps in hospitals through bulk purchase of drugs and equipment, ability to hire senior doctors, referral of complex cases between units, and stronger bargaining with insurers. A regional chain can offset that with deep local trust, strong doctor relationships and focus on underserved catchments such as Bihar and Jharkhand, where demand for quality private beds exceeds supply.

What decides whether Paras Healthcare grows from here is whether it can keep its existing hospitals full with complex cases, recruit and retain senior clinicians, add beds without over-borrowing, and collect cash quickly from insurers and schemes. The RHP identifies a planned 300-bed Gurugram II hospital for FY27 and up to 500 beds at Ludhiana for FY28, taking targeted capacity to 3,011 beds by March 2028. These are planned additions, subject to execution and ramp-up risk, rather than operating capacity already available (RHP p.40).

3. Use of Funds

• Of the fresh issue of up to Rs 500 cr, Rs 320.9 cr is earmarked for repayment or prepayment of company borrowings, and Rs 54.1 cr for investment in wholly owned subsidiary PMHPL to repay or prepay its borrowings: Rs 375 cr in total. The remaining net proceeds are for general corporate purposes; the final balance depends on offer expenses and finalisation of the issue (RHP p.130).
• The offer for sale of up to Rs 950 cr is shares sold by existing shareholders, so that money goes to the selling shareholders and not to the company.

4. Financials Overview

The company lost money in FY24 and FY25, turned profitable in FY26, and reported a strong three-month stub to June 2026. Earnings before interest, tax, depreciation and amortisation, a measure of operating earnings before financing costs and depreciation, rather than operating cash flow, jumped in FY26, while borrowings kept rising.

Three-month periods ended June 30 of the indicated calendar year. Source: RHP pp.88, 460–463; annual periods end March 31.

Revenue from operations grew 24.10% to Rs 1,605.952 cr in FY26 from Rs 1,294.063 cr in FY25, following Rs 1,129.039 cr in FY24. Operating profit rose and the company moved from loss to profit, alongside higher debt. The June quarters are three-month periods and should be compared with the corresponding quarter, rather than with full years for growth (RHP pp.88, 469).

5. What the financials tell us

The financial picture is a recent turnaround funded with substantial debt. Profit has arrived, but it rests on a small earnings base and a sharp margin improvement. The RHP explains volume and cost drivers; the remaining question is whether those gains persist as hospitals mature and new capacity opens.

Turned profitable only in FY26 after two loss years

Paras Healthcare lost about Rs 15.30 cr in FY24 and about Rs 58 cr in FY25, then earned about Rs 43.80 cr in FY26 on an owners basis. Basic earnings per share moved in the same way, from a loss of Rs 1.57 to a loss of Rs 5.94 and then to a profit of Rs 4.34.

That sequence matters for a hospital business. Hospitals carry heavy fixed costs for staff, rent and equipment, so a small rise in occupancy or billing per patient can swing the bottom line from loss to profit. The reverse is also true. One profitable year after two loss years does not yet show that the new level of profit can be held if occupancy slips, doctor costs rise or a new unit takes time to fill.

The June 2026 quarter added about Rs 49.70 cr of profit, already more than the whole of FY26, against a small loss a year earlier. That is a strong quarter, but tax accounting matters: profit before tax was Rs 48.12 cr, and a net tax credit of Rs 1.562 cr lifted PAT to Rs 49.682 cr. One quarter should not be treated as a sustainable annual earnings run rate (RHP pp.88, 468).

Margins improved with utilisation and cost changes; durability remains the test

Operating EBITDA, which strips out other income and fair-value gains from headline EBITDA to show core operating earnings, rose from about Rs 119 cr in FY24 and about Rs 136.30 cr in FY25 to about Rs 312.70 cr in FY26. The operating margin on revenue from operations rose from about 10.5% in both FY24 and FY25 to about 19.5% in FY26.

The RHP attributes revenue growth to patient volumes and specialties, supported by hiring doctors and consultants. FY26 employee expenses rose 4.46% and retainer/consultant fees 9.80%, both below revenue growth of 24.10%. Loss allowances fell as older receivables were collected, and outsourced medical-service costs fell after radiology operations were brought in-house. Together with higher occupancy, these disclosures help explain improved operating leverage. They do not by themselves prove that the margin will persist through expansion (RHP pp.155, 469–471).

The gap between headline EBITDA and operating EBITDA is modest, which helps. In FY26 headline EBITDA was about Rs 335.60 cr against operating EBITDA of about Rs 312.70 cr, so most of the profit came from core operations rather than other income. In the June 2026 stub the same pattern held, with headline EBITDA of about Rs 113.50 cr and operating EBITDA of about Rs 105 cr. That supports the distinction between core operating earnings and other income, while the disclosed utilisation and cost changes help explain the core margin improvement. EBITDA remains distinct from cash collected after working capital, tax and investment.

Borrowings are far larger than equity and keep rising

Total borrowings, which exclude lease liabilities for rented hospital buildings and equipment, rose from about Rs 547.50 cr in FY24 to about Rs 727.90 cr in FY25, about Rs 854.10 cr at March 2026 and about Rs 888.90 cr by June 2026. Total equity at June 2026 was about Rs 445 cr, so borrowings alone were about twice equity on an adjusted basis that excludes leases.

Including leases, total debt was about Rs 1,429.50 cr at June 2026, or about 3.2 times equity. Leases matter a lot for hospitals because many operators run on long rented premises, and rent-like lease charges sit outside bank debt but still must be paid. The fact that leases add more than Rs 540 cr to debt shows how much of the network depends on rented capacity.

Rising debt alongside rising profit can reflect investment in beds and equipment, but also raises financing costs. Outstanding fund-based borrowings were about Rs 939.50 cr at August 2026, above the June level. The IPO earmarks Rs 375 cr for repayment, which should reduce borrowings when deployed; it does not remove ongoing investment and lease obligations. FY26 operating cash flow was Rs 163.512 cr against Rs 169.417 cr of payments for property, plant, equipment and intangible assets. Finance costs paid of Rs 62.508 cr, lease interest paid of Rs 46.103 cr and lease principal of Rs 1.077 cr were separately classified in financing activities, so operating cash flow less capital spending is not cash available after those financing charges (RHP pp.89–90, 130).

Net worth has been rebuilt but remains thin

Net worth, which is what belongs to shareholders after all liabilities, stood at about Rs 445 cr at June 2026, up from about Rs 394.90 cr at March 2026. Net asset value per share rose from Rs 28.74 at March 2025 to Rs 39.11 at March 2026 and Rs 44.06 at June 2026 on pre-issue shares.

FY26 net worth benefited from both profit and an April 2025 preferential allotment of 3,375,527 shares at Rs 237, raising Rs 80 cr gross. The cash-flow statement reports Rs 69.125 cr of net share proceeds. Share count rose from about 9.76 cr in FY24–FY25 to about 10.10 cr by FY26; that relatively small percentage increase does not make the equity funding immaterial. The subsequent June-quarter increase in net worth should be considered separately. Pre-IPO equity remained thin against June borrowings of nearly Rs 890 cr excluding leases and over Rs 1,420 cr including them, while the fresh issue will add capital and fund planned repayments (RHP pp.89, 108, 463, 468).

Return on net worth for FY26 was 12.98% on a consolidated basis. For a business that has just turned profitable, a double-digit return shows the equity is now earning, but it is not yet at the level of the most efficient hospital operators. Return on capital employed for the June 2026 stub was 4.23% including leases and 5.52% excluding them, but a three-month return cannot be read as a yearly return.

What to make of the June quarter

The June 2026 stub earned basic earnings of Rs 4.92 a share in just three months, more than the Rs 4.34 earned in all of FY26. Operating margin in that quarter was about 22.3% on revenue, above the 19.5% for FY26.

The June 2026 quarter included a deferred tax credit of Rs 16.217 cr, primarily from recognising deferred tax assets on unabsorbed depreciation, offset by current tax expense of Rs 14.655 cr. The resulting net tax credit was Rs 1.562 cr. Recurring pre-tax operations and cash collections should therefore be assessed separately from the tax benefit before extrapolating PAT. The test is whether subsequent quarters sustain operating margins and collections without disproportionate new borrowing (RHP pp.88, 468).

6. Valuation Analysis

At the top of the band, the IPO values Paras Healthcare at about 171 times FY26 profit on post-issue shares. It also asks about 7.9 times book after adding the gross fresh issue to June 2026 equity, before issue expenses. The saved market snapshot shows Global at about 69x and Apollo at about 72x, but its valuation date and earnings windows are not supplied, so that comparison is indicative rather than a verified common-basis valuation. The separate RHP comparison uses October 5, 2026 prices and FY26 diluted EPS. The asking multiple remains demanding on the reported FY26 earnings base: the investment case requires sustained operating gains and successful debt repayment, with expansion and cash conversion still material risks.

7. Peer Analysis

Basis: Paras P/E uses post-issue shares and FY26 reported profit of Rs 43.83 cr. The four peer P/Es come from a saved market snapshot; their snapshot date and earnings windows require confirmation. RoNW figures are from the RHP’s FY26 comparison. These P/Es should not be treated as equivalent to the RHP’s dated FY26-EPS multiples.

For these four displayed peers, October 2026 RHP multiples range from about 55x to 92x, while the saved market snapshot ranges from about 69x to 340x. The RHP figures are 91.89x for Aster, 59.36x for Apollo, 55.43x for Fortis and 64.46x for Global, based on October 5, 2026 closing prices and FY26 diluted EPS. Differences between the two sets must not be attributed solely to price moves or earnings weakness without confirming the snapshot’s basis (RHP pp.150–151).

Apollo and Global provide useful valuation references, but excluding other hospital operators requires more than a high market P/E. The four saved snapshot multiples have a median of about 159x, against which Paras appears at a premium of about 3% to 8%. That arithmetic is correct, but does not establish fair value because the earnings windows are unconfirmed. Aster at 340.3x and Fortis at 245.75x cannot be called distressed solely from these multiples; the RHP reports positive FY26 diluted EPS and RoNW for both (RHP pp.150–151).

The relevant picture is different:

• Returns are middling, not best in class. Paras Healthcare earned 12.98% on net worth in FY26, below Apollo at 21.95%, Global at 15.15% and Jupiter at 13.41%, while exceeding Fortis at 11.08%, Aster at 9.70% and Manipal at 12.37% (RHP p.150).
• The earnings base is tiny, so the multiple is fragile. A market value of about Rs 7,165.10 cr to Rs 7,498.30 cr rests on only Rs 43.83 cr of yearly profit, so any slip in occupancy or costs swings what multiple is justified.
• Scale and reach argue for a discount, not a premium. Paras Healthcare runs eight hospitals concentrated in the north and east, while Apollo alone is valued far higher and operates pan-India. Smaller, concentrated chains usually trade below large liquid leaders because a problem in one cluster hurts more.
• The wider set makes the ask look richer. On the October 2026 prospectus basis Paras Healthcare was about 152x to 160x on earnings of Rs 4.34 a share, against a median of 60.73x (about 61x) for all ten RHP peers and names such as Narayana at 43.4x, Jupiter at 42.9x, Yatharth at 55.2x and Max at 62.1x.

The RHP-based valuation comparison supports caution about the price, but the rationale should reflect the available evidence: operating metrics and cash flows are disclosed, margins have identifiable drivers, and Rs 375 cr of IPO proceeds is earmarked for repayment. The question is whether those operating gains and balance-sheet improvements can support the high earnings multiple while planned hospitals ramp up. The saved market-snapshot median is not a reliable common-basis shortcut to fair value.

8. Moat

No durable edge is evidenced beyond local presence

What sets Paras Healthcare apart in the material is focus rather than scale: a specialty-led network concentrated in North India, Bihar and Jharkhand, offering advanced tertiary and quaternary care where quality private supply is limited. That can build local trust, steady referrals from smaller towns and pricing power for complex procedures if senior doctors stay.

Multi-specialty capability, advanced equipment and doctor-led care are also offered by larger peers, so they do not alone establish a durable moat. Paras’s disclosed occupancy and specialty mix provide operating evidence: FY26 occupancy was 61.75%, reaching 83.85% at Gurugram, while oncology contributed 21.63% of revenue. These indicators support analysis of utilisation and local strength, but do not by themselves prove durable pricing power or clinician retention (RHP pp.155–156).

Tailwinds help all hospitals, not this chain alone

Demand for private hospital care in India is supported by rising incomes, more health insurance, ageing, lifestyle disease and short supply of quality beds in states such as Bihar and Jharkhand. Government schemes that pay for treatment of poorer patients also push volumes to empanelled private hospitals.

These forces lift the whole industry and reach Paras Healthcare through available, staffed beds and reimbursement arrangements. The planned Gurugram II and Ludhiana additions provide a disclosed expansion path, while government schemes and PSUs contributed 41.28% of FY26 revenue. The benefit depends on successful commissioning, patient volumes, scheme economics and timely collections (RHP pp.40, 156).

The edge looks narrow and needs proof

Paras Healthcare has a regional position, with higher occupancy and a disclosed expansion pipeline, but those facts do not establish a durable moat. Concentration gives depth in its catchment while exposing it to local competition, doctor moves and pricing action. In this assessment, durability requires sustaining operating EBITDA margins around or above 19%, retaining clinicians, collecting cash and adding capacity without overstretching debt. The multi-year occupancy, revenue-per-bed and cash-flow series should be used to test that thesis as new periods are reported (RHP pp.89, 155–156, 461).

9. Risks

Business and concentration

• Regional concentration: eight hospitals in North India, Bihar and Jharkhand mean a local outbreak, doctor exit, new competitor or pricing curb in one cluster can hurt the whole company, unlike pan-India peers who can offset across states.
• First-year profit risk: one profitable year after two loss years does not prove the margin jump from about 10.5% to about 19.5% will hold, even though the RHP explains volume growth, improving utilisation and cost changes.

Financial and leverage

• Heavy debt load: at June 2026, borrowings were about Rs 888.90 cr excluding leases and total debt about Rs 1,429.50 cr including leases, against equity of about Rs 445 cr. The planned Rs 375 cr repayment should reduce borrowings, but financing and lease obligations remain material if occupancy dips (RHP pp.130, 463).
• Tiny profit cushion: with only Rs 43.83 cr of FY26 profit supporting a market value near Rs 7,500 cr, a small miss in billing or costs has an outsized effect on what multiple is justified. This is specific to Paras Healthcare, not shared by larger profitable peers.
• Cash collection: FY26 operating cash flow of Rs 163.512 cr was below Rs 169.417 cr of capital spending before financing charges. Receivables absorbed Rs 124.682 cr of operating cash, and government/PSU revenue mix rose to 41.28%. Collection timing therefore remains a concrete risk despite the disclosed cash-flow improvement (RHP pp.89–90, 156).

Regulatory and operating

• Price and scheme risk, industry-wide: caps on procedure prices, drugs and implants, plus changes in government scheme rates or insurer bargaining, can squeeze all private hospitals. Regional chains with less bargaining power often feel it more.
• Talent and quality risk: loss of senior clinicians, nurse shortages or a quality lapse can quickly lower occupancy and invite regulatory action. This risk has not shifted in a measurable way in the material, but leverage makes any slip costlier.

10. Verdict

Three facts frame the valuation: FY26 is the profitable year in the disclosed FY24–FY26 period, its earnings base is small relative to the asking market value, and historical debt including leases exceeds three times equity. There are also material improvements: occupancy and operating margins rose for disclosed reasons, and Rs 375 cr of IPO proceeds is intended for repayment. The June quarter was strong but included a deferred tax benefit and should not be annualised. The price requires sustained execution beyond a recent turnaround.

The thesis would work only if the near-20% operating margin holds for full years, profit grows well beyond the FY26 base, and borrowings fall so returns move toward Apollo and Global levels. It would break if occupancy softens, doctor or cost pressures return, collections lag, or any new capacity needs more debt. On an earnings lens the price looks stretched, not fair, for a retail investor seeking steady hospital exposure.

Source basis: supplied Paras Healthcare RHP and desk price-band/capital-structure inputs. RHP references above use PDF page markers in the supplied source text. Saved peer market P/Es are from the article context snapshot and remain subject to the date/earnings-basis caveat in section 7.